MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, BOLT had $4,471K increase in cash & cash equivalents over the period. -$39,922K in free cash flow.

Cash Flow Overview

Change in Cash
$4,471K
Free Cash flow
-$39,922K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of marketable securit...
    • Stock-based compensation expense
    • Non-cash lease expense
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Purchases of marketable securiti...
    • Accounts payable and accrued exp...
    • Others

Cash Flow
2025-12-31
Net loss
-33,376
Depreciation and amortization
1,291
Stock-based compensation expense
2,782
Accretion of discount on marketable securities
670
Gain on sale of fixed assets
288
Asset impairment
0
Non-cash lease expense
2,526
Prepaid expenses and other assets
-76
Accounts payable and accrued expenses
-5,430
Operating lease liabilities, net
-2,251
Deferred revenue
-4,642
Other long-term liabilities
132
Net cash used in operating activities
-39,850
Purchase of property and equipment
72
Proceeds from sales of property and equipment
963
Purchases of marketable securities
29,016
Maturities of marketable securities
72,427
Net cash provided by investing activities
44,302
Proceeds from issuance of common stock
19
Net cash provided by financing activities
19
Net increase (decrease) in cash
4,471
Cash, cash equivalents and restricted cash at beginning of year
8,970
Cash, cash equivalents and restricted cash at end of period
13,441
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Maturities of marketablesecurities$72,427K Proceeds from issuance ofcommon stock$19K Proceeds from sales ofproperty and equipment$963K Net cash provided byinvesting activities$44,302K Net cash provided byfinancing activities$19K Canceled cashflow$29,088K Net increase(decrease) in cash$4,471K Canceled cashflow$39,850K Purchases of marketablesecurities$29,016K Purchase of property andequipment$72K Stock-based compensationexpense$2,782K Non-cash lease expense$2,526K Depreciation andamortization$1,291K Other long-termliabilities$132K Prepaid expenses andother assets-$76K Net cash used inoperating activities-$39,850K Canceled cashflow$6,807K Net loss-$33,376K Accounts payable andaccrued expenses-$5,430K Deferred revenue-$4,642K Operating leaseliabilities, net-$2,251K Accretion of discount onmarketable securities$670K Gain on sale of fixedassets$288K

Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics, Inc. (BOLT)